Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

lilly_entrance_web

Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data

July 31, 2019 Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma

Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …
News
fda2outsideweb

Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019 Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …
News
bacteria-163711_960_720

Cigarette smoke causes superbug to become more drug resistant, study shows

July 30, 2019 Research and Development AMR, MRSA, cigarettes smoke, drug resistance, pharma, smoking

Cigarette smoke can make certain strains of the bacteria Methicillin-resistant Staphylococcus aureus (MRSA) more resistant to antibiotics, according to a …
News
merck-keytruda

MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer

July 30, 2019 Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma

MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …
News
survey-2316468_640

The patient is always right: Extracting the full value of PROMs

July 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PROs, UK, feature, patient reported outcomes, patient-reported outcomes, pharma

Patient-reported outcomes measures are an invaluable tool in ensuring that the patient remains in the driving seat when it comes …
Feature
novartis_side_building

Novartis’ Entresto falls short at Phase 3 in heart failure with preserved ejection fraction

July 29, 2019 Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten

At the end of a week that could certainly be called “eventful” here in the UK – one that saw …
News
london-2393098_960_720

London’s water contains high levels of antibiotic-resistant genes, UCL research reveals

July 26, 2019 Medical Communications, Research and Development London, UCL, UK, antibiotic resistance, pharma

Research from University College London has warned that freshwater sources in the English capital of London contain high levels of …
News

J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis

July 26, 2019 Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod

New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …
News
reshma-bio-image

Vertex promote chief medical officer to CEO as Jeffrey Leiden steps down

July 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Dr Reshma Kewalramani has been made the new Vertex CEO. Vertex’s Chief Medical Officer Dr Kewalramani will succeed current CEO …
Appointment
christi_shaw

Christi Shaw taken on by Gilead as Kite Pharma’s new CEO

July 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Lilly veteran Christi Shaw has joined Kite Pharma as the company’s new CEO. Shaw comes to Gilead’s cancer immunotherapy firm, …
Appointment
opdivo_1_1

BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer

July 25, 2019 Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …
News
30805878966_19824f12fd_z

MRI scans can help predict MS patient’s long term prognosis, 15 year study shows

July 25, 2019 Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma

MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …
News
opioid_naloxone_device

Researchers design automatic opioid overdose antidote device

July 25, 2019 Research and Development naloxone, opioid crisis, opioids, pharma, purdue university

Researchers at Purdue University are developing a device that would automatically detect an overdose in opioid users and release a …
News
jonathan_symonds

GSK hire Jonathan Symonds as new Chairman

July 24, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Business chief Jonathan Symonds has joined British multinational GlaxoSmithKline as the company’s new non-executive chairman. The hire ends GSK’s six …
Appointment
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026